{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:21Z","timestamp":1793212161193,"version":"4.5.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ulcerative proctitis is a common and often highly symptomatic form of inflammatory bowel disease. We performed a systematic review to assess the efficacy of different therapies in the management of patients with ulcerative proctitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified randomized controlled trials in adults with ulcerative proctitis treated with oral or topical therapies for induction of response or remission, or prevention of relapse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 32 randomized controlled trials were included [27 induction\/2839 participants, five maintenance\/334 participants]. Follow-up varied from 3 to 8 weeks for induction, and from 6 to 24 months for maintenance of remission. 5-Aminosalicylic acid [5-ASA] suppository was the most frequently evaluated treatment [14\/32, 43.7%], followed by steroid enema [7\/32, 21.9%]. Topical 5-ASA demonstrated effectiveness for induction of clinical response or remission and prevention of relapse in several studies. Combined topical steroids and 5-ASA was more effective than topical 5-ASA or topical steroids alone to induce response [100% of patients for combination vs 70% for beclomethasone alone and 76% for 5-ASA alone]. One observational study suggested azathioprine may be effective in patients with ulcerative proctitis. Only two cohort studies evaluated the efficacy of tumour necrosis factor inhibitors in ulcerative proctitis. Small molecules, anti-integrins and anti-interleukin therapies have not been evaluated in isolated ulcerative proctitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The role of topical 5-ASA as a treatment for ulcerative proctitis has been confirmed in this systematic literature review, for induction and maintenance of remission. Future trials are needed to investigate the efficacy of more recent and upcoming drug classes in patients with ulcerative proctitis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab218","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T20:13:44Z","timestamp":1638216824000},"page":"922-930","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review"],"prefix":"10.1093","volume":"16","author":[{"given":"B\u00e9n\u00e9dicte","family":"Caron","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine , Vandoeuvre-l\u00e8s-Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of California San Diego , La Jolla, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Schleswig-Holstein , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Diseases Unit, St Mark\u2019s Hospital , Harrow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-6778","authenticated-orcid":false,"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele , Milano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine , Vandoeuvre-l\u00e8s-Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"2022071420382534800_CIT0001","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.2174\/138945011796818117","article-title":"Natural history of ulcerative colitis: current knowledge","volume":"12","author":"Kiss","year":"2011","journal-title":"Curr Drug Targets"},{"key":"2022071420382534800_CIT0002","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"2022071420382534800_CIT0003","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1572-0241.2000.t01-1-01770.x","article-title":"The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII)","volume":"95","author":"Meucci","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2022071420382534800_CIT0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bpg.2018.05.009","article-title":"The treatment of refractory ulcerative colitis","volume":"32\u201333","author":"Pineton de Chambrun","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2022071420382534800_CIT0005","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022071420382534800_CIT0006","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/MIB.0000000000000141","article-title":"Drug therapies for ulcerative proctitis: systematic review and meta-analysis","volume":"20","author":"Lie","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022071420382534800_CIT0007","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/2050640620941345","article-title":"Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort","volume":"8","author":"Dubois","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2022071420382534800_CIT0008","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1365-2036.2010.04293.x","article-title":"Infliximab for refractory ulcerative proctitis","volume":"31","author":"Bouguen","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0009","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.dld.2016.12.001","article-title":"Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study","volume":"49","author":"Mallet","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2022071420382534800_CIT0010","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cgh.2019.05.060","article-title":"Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis","volume":"18","author":"Pineton de Chambrun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382534800_CIT0011","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2022071420382534800_CIT0012","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"2022071420382534800_CIT0013","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"2022071420382534800_CIT0014","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"2022071420382534800_CIT0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"2022071420382534800_CIT0016","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2022071420382534800_CIT0017","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2022071420382534800_CIT0018","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2022071420382534800_CIT0019","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2022071420382534800_CIT0020","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S2468-1253(20)30301-0","article-title":"Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial","volume":"5","author":"Atreya","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022071420382534800_CIT0021","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/gutjnl-2021-324108","article-title":"Drug development for ulcerative proctitis: current concepts","volume":"70","author":"Caron","year":"2021","journal-title":"Gut"},{"key":"2022071420382534800_CIT0022","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"Higgins","year":"2019","edition":"2"},{"key":"2022071420382534800_CIT0023","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2022071420382534800_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"2022071420382534800_CIT0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gut.3.3.207","article-title":"A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis","volume":"3","author":"Lennard-Jones","year":"1962","journal-title":"Gut"},{"key":"2022071420382534800_CIT0026","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/bmj.3.5766.84","article-title":"Betamethasone 17-valerate and prednisolone 21-phosphate retention enemata in proctocolitis. A multicentre trial","volume":"3","author":"Lennard-Jones","year":"1971","journal-title":"Br Med J"},{"key":"2022071420382534800_CIT0027","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.21.7.632","article-title":"Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine","volume":"21","author":"van Hees","year":"1980","journal-title":"Gut"},{"key":"2022071420382534800_CIT0028","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"key":"2022071420382534800_CIT0029","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01312468","article-title":"Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories","volume":"32","author":"Williams","year":"1987","journal-title":"Dig Dis Sci"},{"key":"2022071420382534800_CIT0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004836-198804000-00013","article-title":"Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis","volume":"10","author":"van der Heide","year":"1988","journal-title":"J Clin Gastroenterol"},{"key":"2022071420382534800_CIT0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2036.1988.tb00668.x","article-title":"Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis","volume":"2","author":"van Hogezand","year":"1988","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0032","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/00365528809090161","article-title":"Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial","volume":"23","author":"Mulder","year":"1988","journal-title":"Scand J Gastroenterol"},{"key":"2022071420382534800_CIT0033","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00004836-198808000-00012","article-title":"5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?","volume":"10","author":"Campieri","year":"1988","journal-title":"J Clin Gastroenterol"},{"key":"2022071420382534800_CIT0034","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2036.1994.tb00335.x","article-title":"Budesonide enema in active haemorrhagic proctitis\u2013a controlled trial against hydrocortisone foam enema","volume":"8","author":"Tarpila","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/00365529509093256","article-title":"Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens","volume":"30","author":"Farup","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"2022071420382534800_CIT0036","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00042737-199606000-00010","article-title":"Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg\/2 g) as retention enemas in active ulcerative proctitis","volume":"8","author":"Mulder","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022071420382534800_CIT0037","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1046\/j.1365-2036.1996.81253000.x","article-title":"Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis\u2013a randomized single-blind comparative study","volume":"10","author":"Ardizzone","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1365-2036.1997.126297000.x","article-title":"Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis","volume":"11","author":"Lucidarme","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0039","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","author":"Gionchetti","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"2022071420382534800_CIT0040","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1046\/j.1365-2036.2000.00784.x","article-title":"Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study","volume":"14","author":"Pokrotnieks","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0041","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248.x","article-title":"Delayed-release oral mesalamine at 4.8 g\/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial","volume":"100","author":"Hanauer","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"2022071420382534800_CIT0042","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.MIB.0000171277.70404.40","article-title":"Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study","volume":"11","author":"Lamet","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"2022071420382534800_CIT0043","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2036.2006.02743.x","article-title":"Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis","volume":"23","author":"Gross","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0044","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1365-2036.2007.03468.x","article-title":"Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis","volume":"26","author":"Eliakim","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0045","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/ibd.21258","article-title":"Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis","volume":"16","author":"Andus","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2022071420382534800_CIT0046","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/apt.12362","article-title":"Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation \u2013 a placebo-controlled study","volume":"38","author":"Watanabe","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0047","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1089\/acm.2012.0296","article-title":"Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild\/moderate ulcerative proctitis: a double-blind randomized clinical trial","volume":"19","author":"Zhang","year":"2013","journal-title":"J Altern Complement Med"},{"key":"2022071420382534800_CIT0048","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.gastro.2015.01.037","article-title":"Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis","volume":"148","author":"Sandborn","year":"2015","journal-title":"Gastroenterology"},{"key":"2022071420382534800_CIT0049","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2017.02.027","article-title":"Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis","volume":"15","author":"Lawrance","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382534800_CIT0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cgh.2018.04.027","article-title":"Budesonide suppositories are effective and safe for treating acute ulcerative proctitis","volume":"17","author":"Kruis","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382534800_CIT0051","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.cgh.2019.09.049","article-title":"No superiority of tacrolimus suppositories vs beclomethasone suppositories in a randomized trial of patients with refractory ulcerative proctitis","volume":"18","author":"Lie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382534800_CIT0052","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/gut.35.9.1282","article-title":"Optimum dose of olsalazine for maintaining remission in ulcerative colitis","volume":"35","author":"Travis","year":"1994","journal-title":"Gut"},{"key":"2022071420382534800_CIT0053","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.1998.228_a.x","article-title":"Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group","volume":"93","author":"d\u2019Albasio","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"2022071420382534800_CIT0054","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gut.42.2.195","article-title":"Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study","volume":"42","author":"Marteau","year":"1998","journal-title":"Gut"},{"key":"2022071420382534800_CIT0055","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1572-0241.2000.02185.x","article-title":"Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis","volume":"95","author":"Hanauer","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2022071420382534800_CIT0056","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1440-1746.2012.07215.x","article-title":"Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis","volume":"27","author":"Fukunaga","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"2022071420382534800_CIT0057","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1365-2036.1997.00193.x","article-title":"Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy","volume":"11","author":"Brown","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382534800_CIT0058","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.2042-7158.1985.tb05058.x","article-title":"Disposition of radiolabelled suppositories in humans","volume":"37","author":"Jay","year":"1985","journal-title":"J Pharm Pharmacol"},{"key":"2022071420382534800_CIT0059","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1007\/BF01308084","article-title":"Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis","volume":"37","author":"Campieri","year":"1992","journal-title":"Dig Dis Sci"},{"key":"2022071420382534800_CIT0060","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/bmj.2.6194.822","article-title":"Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis","volume":"2","author":"Farthing","year":"1979","journal-title":"Br Med J"},{"key":"2022071420382534800_CIT0061","first-page":"753","article-title":"Enema volume as an important factor in successful topical corticosteroid treatment of colitis","volume":"67","author":"Swarbrick","year":"1974","journal-title":"Proc R Soc Med"},{"key":"2022071420382534800_CIT0062","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2022071420382534800_CIT0063","first-page":"19","author":"European Medicines Agency","year":"2018"},{"key":"2022071420382534800_CIT0064","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"2022071420382534800_CIT0065","author":"Clinical Trials.gov","year":"2020"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab218\/41887743\/jjab218.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/922\/44890516\/jjab218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/922\/44890516\/jjab218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T20:40:06Z","timestamp":1657831206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/6\/922\/6446868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,11,30]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab218","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,11,30]]}}}